[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpes-zoster\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpes-zoster":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,46,78,107,143,166,185,212,235,258,280,303,320,336,351,366,383,400,420,445,481,501,523,548,569],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100483855","phase-1-safety-and-immunogenicity-of-recombinant-varicella-zoster-virus-vaccine-in-people-with-hiv-who-have-a-cd4-count-less-than-300-or-greater-than-or-equal-to-300-and-a-healthy-control-population-100483855",false,"NCT05580458","Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population","Phase 1\u002F2 Open-label Trial of Safety and Zoster Immunogenicity Evaluation for People With HIV With CD4 Counts Under and Above 300 and Healthy Volunteers Following Shingrix Vaccination (ZEUS)","* INCLUSION CRITERIA:\n\nGeneral Inclusion Criteria:\n\nIndividuals must meet all of the following criteria to be eligible for study participation:\n\n* Able to provide informed consent.\n* Participants of childbearing potential must agree to use at least 1 acceptable method of contraception when engaging in sexual activities that can result in pregnancy, beginning at screening through month 3. Acceptable methods of contraception include the following:\n\n  * Hormonal contraception.\n  * Male or female condom.\n  * Diaphragm or cervical cap with a spermicide.\n  * Intrauterine device.\n* Has a primary care provider.\n\nAdditional Inclusion Criteria for People with HIV:\n\n* PWH must also meet all the following criteria to be eligible for study participation:\n* \\>= 18 years of age.\n* Seropositive for HIV-1 (documented or confirmed at screening).\n* Documented viral load \\\u003C 100 copies\u002FmL within 90 days of screening and documented viral suppression defined as viral load consistently \\\u003C100 copies\u002FmL with at least one documented viral load \\\u003C 40 copies\u002FmL within 12 months prior to screening.\n* Currently on a stable antiretroviral regimen (minimum of 6 months of a stable ART regimen; changes for side effects, drug interaction, or convenience allowed), or is an elite controller (maintains undetectable viral loads in the absence of any treatment for a period of 12 months prior to screening visit).\n* No active\u002Funcontrolled opportunistic infections (patients on chronic maintenance therapy would be considered as controlled).\n\nAdditional Inclusion Criteria for Healthy Volunteers:\n\nHealthy volunteers must also meet all of the following criteria to be eligible for study participation:\n\n* \\>= 50 years of age.\n* No uncontrolled chronic medical issues that per the discretion of the PI or designee would compromise the safety of the research participant.\n* No underlying immunodeficiencies (including negative HIV test at screening).\n\nEXCLUSION CRITERIA:\n\nIndividuals meeting any of the following criteria will be excluded from study participation:\n\n* Previous receipt of Shingrix vaccine at any time.\n* Receipt of Zostavax within the past 12 months.\n* History of severe allergic reaction to any component of Shingrix.\n* Diagnosed varicella or herpes zoster episode within the past 1 month. Subject will be eligible for SHINGRIX vaccine once symptoms of herpes zoster episode have resolved.\n* Immunocompromised (other than HIV for the PWH cohort) within the past 6 months (eg, due to a malignancy other than skin cancer).\n* Current moderate or severe acute illness (ie, febrile illness, seizure, myocardial infarction, cerebrovascular accident, pulmonary embolism) that in the opinion of the principal investigator, would make the subject unsuitable for the study.\n* Pregnancy or breastfeeding.\n* Receipt of an investigational agent, investigational vaccine, or licensed live virus vaccine within 30 days prior to screening.\n* Planned receipt of any vaccine (investigational or ACIP-recommended) between months 0 and 2 except for the tetanus, diphtheria, and pertussis vaccine \\[TDaP\\], Pneumovax, inactivated influenza vaccines, and COVID-19 vaccine which may be given at least 8 days before and\u002For at least 14 days after each study agent injection (at month 0\u002Fmonth 2).\n* Administration of immunoglobulins or any blood products within 90 days preceding the first dose of vaccine or planned administration during the study period.\n* Chronic administration (\\>= 15 consecutive days) of immunosuppressive or other immune-modifying drugs within 6 months before screening. (Prednisone \\\u003C 20 mg\u002Fday or equivalent, corticosteroid nasal spray or inhaler, and topical steroids are not exclusionary).\n* Uncontrolled psychiatric disease per physician evaluation, current substance use, or inappropriate conduct unsuitable for a research study.\n* Any condition that could compromise, in the investigator's opinion, the participant's safety or the study outcomes.\n\nParticipants will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as sex, race, ethnicity, socioeconomic status, etc, except for age.\n\nMedical record review may be used for determining eligibility. If a clinical laboratory evaluation is available for review at the screening timepoint, but was obtained prior to protocol consent, the laboratory test does not have to be repeated for the purposes of confirming eligibility under the protocol.",true,"ALL","18 Years",{"count":21,"type":22},225,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nShingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18. Researchers want to learn more about how people with HIV respond to Shingrix.\n\nObjective:\n\nTo learn how Shingrix affects the immune response in people with HIV.\n\nEligibility:\n\nPeople aged 18 years and older with HIV. Healthy people aged 50 years or older are also needed.\n\nDesign:\n\nParticipants will have at least 4 clinic visits in 1 year.\n\nParticipants will be screened. They will have a physical exam with blood and urine tests.\n\nAt their first visit, participants will receive Shingrix as a shot in the upper arm. They will have a rectal swab; a cotton swab will be inserted into the rectum and rotated gently to collect bacteria.\n\nParticipants will receive a second shot of Shingrix 2 months after the first one. They will visit the clinic again 3 and 12 months after the first shot.\n\nParticipants will receive a 28-day memory tool. They will write down their symptoms between clinic visits. They will have up to 4 phone calls to talk about side effects of the shot.\n\nParticipants may undergo apheresis: They will lie still while blood is drawn from a needle in one arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be given back through a second needle in their other arm.",[29],"Herpes Zoster",[31,32],"HERPES ZOSTER","Shingrix Vaccine","RECRUITING","2026-06-04",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":37},"2023-03-13",{"date":41,"type":22},"2027-10-01",{"name":43,"class":44},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100631582","phase-4-a-study-to-evaluate-the-effect-of-recombinant-zoster-vaccine-on-new-diagnosis-of-dementia-in-an-older-adult-population-aged-76-years-or-older-in-finland-100631582","NCT07502560","A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland","A Randomized, Placebo Controlled, Observer-blind, Phase IV Pragmatic Trial to Evaluate the Effect of Recombinant Zoster Vaccine (Shingrix) on Incident Dementia Diagnosis in an Older Adult Population Aged ≥76 Years in Finland","Inclusion Criteria:\n\n* Citizens living permanently in Finland, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure. Informed consent will include consent to access health register data for participants.\n* Age 76 years or older at the time of signing the informed consent.\n\nExclusion Criteria:\n\n* Prior receipt of a Herpes Zoster (HZ) vaccine.\n* History of dementia diagnosis prior to enrolment, including confirmed cases or those under investigation. This includes:\n\n  * History of a confirmed clinical diagnosis of dementia prior to enrolment.\n  * Prior or current use of medications intended to treat dementia.\n  * Current or recent history of cognitive assessments for any memory deficit or suspected dementia before enrolment including investigations that are ongoing or that were inconclusive (but not those for which dementia was conclusively ruled out); mild cognitive impairment on its own without any other information to indicate cognitive decline or dementia will not result in exclusion.\n* Severely immunocompromised individuals.\n* Concurrently participating in another clinical trial, in which the participant has been or will be exposed to an investigational product or ongoing participation in trials focused on preventive dementia interventions.\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.\n* Living in a nursing facility.","76 Years",{"count":55,"type":22},33609,[57],"PHASE4","The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.",[29],[61,62,29,63,64,65,66],"Recombinant Zoster Vaccine","Shingrix","Incident dementia","Alzheimer's Disease","Older adults","Finland","2026-05-08",{"date":69,"type":37},"2026-05-12",{"date":71,"type":37},"2026-03-31",{"date":73,"type":22},"2037-03-31",{"name":75,"class":76},"GlaxoSmithKline","INDUSTRY",8,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100639823","long-term-effectiveness-of-the-live-attenuated-herpes-zoster-vaccine-100639823","NCT07585370","Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine","Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years or Older: a Multicenter, Retrospective Cohort Study Based on Phase III Trial","Inclusion Criteria:\n\n1. Individuals included in the E-mFAS from the Phase III Clinical Trial (NCT04334577) of the live attenuated herpes zoster vaccine produced by Changchun BCHT biotechnology Co. conducted during 2020-2021.\n2. Individuals who were able to complete the study with verbal informed consent.\n\nExclusion Criteria:\n\n1. Individuals who developed herpes zoster during the original Phase III Clinical Trial follow-up period.\n2. Individuals who were known to have died before the retrospective study.","40 Years",{"count":87,"type":22},24740,"OBSERVATIONAL","This is a multicenter retrospective cohort study to evaluate the long-term effectiveness of the live attenuated herpes zoster vaccine within 6 years after vaccination. We plan to select 24,740 participants who were non-herpes zoster cases in the modified Full Analysis Set for Efficacy (E-mFAS) from the Phase III Clinical Trial (NCT04334577) of the live attenuated herpes zoster vaccine manufactured by Changchun BCHT Biotechnology Co. conducted during 2020-2021. In the original Phase III Clinical Trial, the participants were randomly assigned to the vaccine group and the placebo group at a 1:1 ratio to receive one dose of the live attenuated herpes zoster vaccine (with varicella-zoster virus \\>=4.3 lg PFU per 0.5 mL dose) or one dose of placebo (with no varicella-zoster virus component), respectively. This study uses a stage-based design. In Stage 1, participants originally assigned to the vaccine group and those originally assigned to the placebo group will be compared to assess the cumulative incidence of herpes zoster from the end of the original Phase III Clinical Trial in July 2021 to the marketing authorization of the vaccine in China in June 2023. In Stage 2, after marketing authorization of the vaccine in China in June 2023, a large proportion of the participants originally assigned to the placebo group received catch-up vaccination and thereby formed a catch-up vaccination group. These stage-specific groups will be compared to evaluate the relative waning of protection in participants who received catch-up vaccination compared with participants vaccinated in the original Phase III Clinical Trial. In addition, among participants originally assigned to the placebo group who received catch-up vaccination, the incidence of herpes zoster during the post-catch-up vaccination period will be compared with the incidence during their earlier placebo period before catch-up vaccination, in order to evaluate the relative risk of herpes zoster under vaccinated versus placebo exposure. For this study, telephone surveys will be conducted using a standardized questionnaire to collect data on herpes zoster occurrence from participants, with verbal informed consent obtained prior to the survey. Face-to-face interviews will also be conducted to verify reported herpes zoster cases. Moreover, their past medical history and lifestyle information will be collected.",[29],[92,93,94,95,96,29],"Virus Diseases","Infections","DNA Virus Infections","Herpesviridae Infections","Varicella Zoster Virus Infection","2026-05-07",{"date":99,"type":37},"2026-05-13",{"date":101,"type":37},"2026-03-06",{"date":103,"type":22},"2026-06-30",{"name":105,"class":106},"Jiangsu Province Centers for Disease Control and Prevention","NETWORK",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100636768","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-herpes-zoster-associated-pain-100636768","NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","85 Years",{"count":5,"type":22},[118],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[29,121,122,123,124],"Zoster-Associated Pain","Postherpetic Neuralgia","Neuropathic Pain","Acute Pain",[126,127,128,129,29,130,122,123,131,132,133],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Analgesia","Non-pharmacological Intervention","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":67,"type":37},{"date":138,"type":22},"2026-05-01",{"date":140,"type":22},"2026-07-10",{"name":142,"class":76},"Nakhia Impex LLC",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100620759","the-analgesic-efficacy-and-safety-of-venlafaxine-for-prevention-of-postherpetic-neuralgia-in-patients-with-acute-herpes-zoster-100620759","NCT07361796","The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Venlafaxine) for Prevention of Postherpetic Neuralgia in Acute Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 30 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. HZ with head, neck, ocular, mucous membrane, cranial nerve, or central nervous system involvement or generalized HZ;\n* 2.Known hypersensitivity to venlafaxine;\n* 3.History of major depressive disorder requiring antidepressant therapy;\n* 4.History of systemic immune diseases, organ transplantation, or cancers;\n* 5.Pregnancy or lactation;\n* 6.Presence of acute or chronic pain disorders other than HZ.",{"count":151,"type":22},832,[118],"Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life. Current treatments for acute HZ pain have limited efficacy in preventing PHN, highlighting the need for effective preventive strategies targeting early pathophysiological mechanisms. Venlafaxine as a plausible and clinically relevant candidate for early intervention to prevent the transition from acute HZ pain to PHN.",[29,155,122],"Pain","2026-03-23",{"date":158,"type":37},"2026-03-27",{"date":160,"type":37},"2025-12-15",{"date":162,"type":22},"2027-12-31",{"name":164,"class":165},"Beijing Tiantan Hospital","OTHER",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":184,"locationsCount":45},"100616558","the-analgesic-efficacy-and-safety-of-mirogabalin-in-patients-with-herpes-zoster-100616558","NCT07307170","The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Mirogabalin) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 30 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of taking gabapentin or pregabalin;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the mirogabalin;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding;\n* 6\\. Suffering from acute or chronic pain disorders other than HZ;\n* 7\\. Patients with severe psychiatric disorders, or cognitive impairment.",{"count":174,"type":22},750,[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Gabapentinoids such as gabapentin and pregabalin are recommended adjuncts, but their efficacy in acute HZ is inconsistent and often accompanied by adverse effects that limit tolerability. Mirogabalin, a newer gabapentinoid approved for peripheral neuropathic pain, has higher affinity and slower dissociation from the α2δ-1 subunit, suggesting stronger analgesia with fewer central side effects. However, its role in managing acute HZ pain remains unknown. We therefore hypothesize that adding mirogabalin to conventional therapy will provide superior pain relief compared with standard treatment alone, and propose a prospective, randomized, controlled, open-label, blinded-endpoint trial to evaluate this.",[29,178,155],"Mirogabalin","2026-03-17",{"date":181,"type":37},"2026-03-19",{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":17,"sex":18,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100629971","phase-2-safety-and-immunogenicity-of-cvi-vzv-001-in-adults-aged-50-years-and-above-100629971","NCT07481604","Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Healthy adults aged 50 years or older\n  * Able to understand the study procedures and provide written informed consent\n  * Females and males of reproductive potential must agree to use medically acceptable contraception until 3 months after the last vaccination\n  * Females of childbearing potential must have a negative pregnancy test prior to vaccination\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  * History of herpes zoster prior to screening\n  * History of severe allergic reaction to vaccines or vaccine components\n  * Known immunodeficiency or immune dysfunction\n  * Prior vaccination with varicella or herpes zoster vaccine\n  * Use of immunosuppressive therapy or systemic steroids that may affect immune response\n  * Positive test for HCV, HBV, or HIV at screening\n  * Pregnant or breastfeeding women\n  * Any medical condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation","50 Years",{"count":194,"type":22},135,[26],"To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.",[29],[199,200,201,202],"Herpes Zoster Vaccine","Shingles","Varicella Zoster Virus","Immunogenicity","2026-03-16",{"date":181,"type":37},{"date":206,"type":22},"2026-04",{"date":208,"type":22},"2027-01",{"name":210,"class":76},"CHA Vaccine Institute Co., Ltd.",7,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},"100363022","phase-1-a-study-to-test-glaxosmithklines-gsk-candidate-vaccine-gsk1437173a-for-prevention-of-shingles-in-children-with-kidney-transplant-100363022","NCT04006808","A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant","A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ\u002Fsu) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients","Inclusion Criteria:\n\n* Subjects' parent(s)\u002FLegally Acceptable Representative(s) \\[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol\n* Written or witnessed\u002Fthumb printed informed consent obtained from the parent(s)\u002FLAR(s) of the subject prior to performance of any study specific procedure.\n* Written informed assent obtained from the subjects when applicable according to local requirements.\n* A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1)\n* Body weight ≥ 6 kg\u002F13.23 pounds.\n* A subject is eligible if they meet at least one of the following criteria:\n\n  * Documented previous VZV vaccination OR\n  * Medically verified varicella (with source documentation) OR\n  * Seropositive for VZV prior to transplantation.\n* Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1)\n* Subject who has received an ABO compatible allogeneic renal transplant (allograft).\n* Subject with stable renal function with stability defined as \\\u003C20% variability between the last two creatinine measurements or based on investigator opinion after review of multiple creatinine measurements.\n* Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to randomization (Visit Day 1).\n* Female subjects of childbearing potential may be enrolled in the study, if the subject\n\n  * has practiced adequate contraception for 30 days prior to Visit Day 1 and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series\n\nExclusion Criteria:\n\nMedical conditions\n\n* Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft\n* Evidence of recurrent primary kidney disease within the current allograft\n* Previous allograft loss secondary to recurrent primary kidney disease\n* History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted).\n* Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment\n* Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant\n* VZV serostatus unknown prior to transplant\n* Subjects with advanced chronic kidney disease\n* Evidence of significant proteinuria (≥ 200 g\u002Fmol creatinine) believed to be of renal origin (an example of non-renal origin is proteinuria from mucus in a reconstructed bladder)\n* Subjects without multiple dialysis options in the event acute or chronic dialysis needed.\n* History of unstable or progressive neurological disorder.\n* Subjects ≤ 5 years of age with a history of one or more simple or complex febrile seizures\n* Subjects \\> 5 years with history of one or more complex febrile seizures\n* Occurrence of a varicella or HZ episode by clinical history within the 6 months (180 days) preceding Visit Day 1\n* Any autoimmune disease, with the following exceptions which do not constitute an exclusion criterion:\n\n  * IgA nephropathy\n  * Rapidly progressive glomerulonephritis\n  * Membranous glomerulonephritis\n  * Idiopathic Type I membranoproliferative glomerulonephritis\n  * Diabetes mellitus (type 1 and 2) with diabetic nephropathy\n* Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency disease\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine\n* Any condition which, in the judgement of the investigator would make intramuscular injection unsafe.\n* Atypical Haemolytic Uraemic Syndrome.\n\nPrior\u002FConcomitant therapy\n\n* Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned use during the study period.\n* Subject in receipt of treatment for rejection during the six months (180 days) prior to enrolment.\n* Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day 1 or planned administration during the duration of the study.\n* Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned administration during the duration of the study.\n* Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned administration of immunoglobulins during the duration of the study.\n* Administration or planned administration of a vaccine within 30 days prior to Visit Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days prior to or 14 days after Visit Month 1.\n* Previous vaccination against HZ\n* Varicella vaccination within the 6 months (180 days) preceding Visit Day 1\n* Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine\n\nPrior\u002FConcurrent clinical study experience\n\n• Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product\n\n* available locally through compassionate use programs,\n* submitted for and pending local\u002Fcountry registration,\n* approved and registered for use in other countries with well-documented Summary of Product Characteristics or Prescribing Information\n* The name of the active component(s) of these immunosuppressants must be provided in the concomitant medication listing\n\nOther exclusions\n\n* Child in care\n* Pregnant or lactating female\n* Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) between one month (30 days) prior to Visit Day 1 through two months (60 days) after Visit Month 1.\n* Evidence or high suspicion, in the opinion of the investigator, of non-compliance or non-adherence to use of induction and\u002For maintenance immunosuppressive therapies.\n* Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit\n\n  * Completion must cover the 7 days immediately prior to randomisation (Visit Day 1).\n  * Completion is defined as a minimum of 6 days completed.\n  * Subjects with less than 6 days completed may be offered a new date for Visit Day 1 and the opportunity to comply with the completion of the 7-day pre-vaccination diary card prior to the new planned Visit Day 1.\n* Any study personnel or their immediate dependants, family, or household member.","1 Year","17 Years",{"count":222,"type":22},184,[25,26],"The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ\u002Fsu, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years",[29],"2026-02-24",{"date":228,"type":37},"2026-02-27",{"date":230,"type":37},"2019-10-25",{"date":232,"type":22},"2027-03-31",{"name":75,"class":76},31,{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":45},"100623746","erector-spinae-plane-block-versus-transcutaneous-radiofrequency-in-postherpetic-neuralgia-100623746","NCT07400640","Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia","Which Is More Effective in the Treatment of Postherpetic Neuralgia: Erector Spinae Plane Block or Transcutaneous Radiofrequency?","Inclusion Criteria:\n\nDiagnosis of postherpetic neuralgia involving cervical, thoracic, or lumbar regions\n\nAge between 18 and 80 years\n\nPersistent pain despite conservative treatment\n\nBaseline VAS score \\> 5\n\nExclusion Criteria:\n\nOphthalmic or extremity postherpetic neuralgia\n\nAllergy to local anesthetics\n\nPregnancy\n\nCoagulopathy or use of antiplatelet therapy\n\nCognitive impairment preventing informed consent","80 Years",{"count":244,"type":22},50,"This observational study aims to compare the effectiveness of ultrasound-guided erector spinae plane (ESP) block and transcutaneous radiofrequency (RF) treatment in patients with postherpetic neuralgia. Pain intensity and neuropathic pain characteristics will be evaluated using the Visual Analog Scale (VAS) and the Self-Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score.",[122,123,29],[248],"postherpetic neuralgia, esp block, transcutaneous rf","2026-02-23",{"date":251,"type":37},"2026-02-25",{"date":253,"type":37},"2025-06-01",{"date":255,"type":22},"2026-10-01",{"name":257,"class":165},"Diskapi Teaching and Research Hospital",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":45},"100623697","phase-1-study-to-evaluate-the-safety-and-immunogenicity-of-a-lyophilized-herpes-zoster-virus-mrna-vaccine-100623697","NCT07400003","Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","A Randomized, Double-Blind, Controlled Phase I\u002FII Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of a Lyophilized Herpes Zoster Virus mRNA Vaccine in Adults Aged 40 Years and Older","Inclusion Criteria:\n\n* Phase I: Age ≥ 40 years; Phase II: Age ≥ 50 years;\n* Participants are able to understand and voluntarily sign the informed consent form;\n* Able to provide legal identification;\n* Participants of childbearing potential and their sexual partners agree to voluntarily adopt effective contraceptive measures from the signing of the informed consent form until 6 months after the last dose of the investigational vaccine, with no plans for sperm or egg donation;\n* Agree to comply with the visit schedule, sample collection, vaccination, and other trial procedures throughout the study period, and remain accessible at all times during the trial.\n\nExclusion Criteria:\n\n* History of chickenpox or herpes zoster in adulthood;\n* History of chickenpox or herpes zoster vaccination (including administration of registered products or participation in clinical trials of chickenpox or herpes zoster vaccines);\n* Close contact with patients infected with chickenpox or herpes zoster within the past 30 days;\n* Clinically significant abnormalities in protocol-specified clinical laboratory tests prior to vaccination (applicable to Phase I clinical trials only):\n\nA. Hematological parameters: White blood cell count (WBC), hemoglobin (Hb), platelet count (Plt); B. Blood biochemical parameters: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), fasting blood glucose (Glu), creatinine (CR); C. Urinalysis parameter: Urine protein (PRO); D. Coagulation parameters: Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), international normalized ratio (INR); E. 12-lead electrocardiogram (ECG).\n\n* Poorly controlled chronic diseases or significant medical history, including but not limited to cardiovascular diseases (e.g., poorly controlled hypertension defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg for participants aged 40-59 years prior to enrollment, or systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg for participants aged ≥60 years), metabolic disorders (e.g., poorly controlled diabetes), hematological diseases, hepatic or renal diseases, digestive system diseases, respiratory system diseases, history of major organ transplantation, or malignancy within the past five years;\n* History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that increases the risk of myocarditis or pericarditis;\n* Autoimmune diseases, immunodeficiency diseases, or family history thereof (including but not limited to psoriasis, systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, acute disseminated encephalomyelitis, facial paralysis, hypersensitivity reactions, polymyalgia rheumatica, rheumatoid arthritis, Guillain-Barré syndrome, asplenia, functional asplenia, HIV infection);\n* Coagulation disorders (e.g., coagulation factor deficiencies, platelet abnormalities, or other coagulopathies);\n* Current or previous severe neurological disorders (epilepsy, convulsions, or seizures) or psychiatric illnesses, or family history of psychiatric disorders;\n* Acute illnesses or acute exacerbations of chronic diseases within the past 7 days, or known or suspected active infections;\n* Immunosuppressive therapy or other immunomodulatory treatments (prednisone ≥20 mg\u002Fday or equivalent for \\>14 days), cytotoxic therapy within the past 6 months, or planned use during the trial;\n* Administration of immunoglobulins or other blood products within the past 3 months (use of hepatitis B immunoglobulin within the past 1 month), or planned use during the trial;\n* Participation in other clinical studies within the past 30 days or planned participation during this trial;\n* Vaccination with live-attenuated vaccines or nucleic acid vaccines within the past 28 days, or vaccination with subunit, inactivated, or other types of vaccines within the past 14 days;\n* Known allergy to vaccines or vaccine components, such as urticaria, dyspnea, or angioedema following vaccination;\n* Pregnancy, lactation, or positive urine pregnancy test in female participants;\n* Fever (axillary temperature ≥37.3°C) within 3 days prior to vaccination or use of antipyretics, analgesics, or antihistamines (e.g., acetaminophen, ibuprofen, loratadine, cetirizine, etc.) as reported during inquiry;\n* Physical examination deemed unsatisfactory on the day of planned vaccination;\n* Skin lesions, inflammation, ulcers, rashes, scars, or other conditions at the target injection site that may interfere with administration or local reaction assessment;\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial.",{"count":266,"type":22},519,[25,26],"This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.",[29,270],"mRNA Vaccine","2026-02-02",{"date":273,"type":37},"2026-02-10",{"date":275,"type":37},"2026-01-06",{"date":277,"type":22},"2027-04-30",{"name":279,"class":76},"Sinovac Biotech Co., Ltd",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":17,"sex":287,"minAge":192,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":301,"locationsCount":45},"100565520","electroacupuncture-regulation-of-immune-cells-in-herpes-zoster-100565520","NCT06643247","Electroacupuncture Regulation of Immune Cells in Herpes Zoster","The Regulatory Mechanisms of Electroacupuncture Intervention on Immune Cells in Herpes Zoster","Inclusion Criteria for HZ:\n\n* Meets HZ diagnostic criteria;\n* Female, aged between 50 and 70 years;\n* Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;\n* Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;\n* Willing to participate in the trial and has signed the informed consent form.\n\nInclusion Criteria for HC:\n\n* No history of HZ or major cardiovascular, respiratory, digestive, urinary, hematologic, endocrine, or neurological diseases;\n* Age-matched female HC volunteers for the HZ group;\n* Clear consciousness and ability to communicate normally;\n* Fully understands the study protocol, demonstrates good compliance, and is willing to cooperate with the study;\n* Has signed a written informed consent form.\n\nExclusion Criteria:\n\n* Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;\n* Women who are planning to conceive, pregnant, or breastfeeding;\n* Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;\n* Patients with bleeding tendencies;\n* Use of corticosteroids or immunosuppressants within the past month.","FEMALE","70 Years",{"count":77,"type":22},[118],"Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life. The immune system is critical in HZ pathogenesis. Studies show acupuncture relieves pain, modulates immunity, and may lower postherpetic neuralgia (PHN) risk. However, evidence is limited on whether electroacupuncture (EA) alleviates HZ by modulating immune cells. Using mass cytometry (CyTOF), this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity. This study will recruit HZ patients and healthy controls (HC), dividing patients into medication-only and medication+EA groups to assess EA's potential immunomodulatory effects in HZ treatment.",[29,293,294],"Electroacupuncture","Immune","2026-02-01",{"date":297,"type":37},"2026-02-03",{"date":299,"type":37},"2024-11-11",{"date":162,"type":22},{"name":302,"class":165},"First People's Hospital of Hangzhou",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":319,"locationsCount":45},"100622010","the-analgesic-efficacy-and-safety-of-loxoprofen-sodium-patch-in-patients-with-herpes-zoster-100622010","NCT07378059","The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Topical Patches (Loxoprofen Sodium Patch) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of taking loxoprofen sodium patch;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the loxoprofen sodium patch;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding.",{"count":174,"type":22},[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Topical NSAIDs offer a promising alternative by delivering localized analgesia with reduced systemic exposure. Therefore, investigators hypothesize that loxoprofen sodium patch may effectively reduce the severity of HZ pain without significantly increasing adverse events.",[29,155],"2026-01-22",{"date":316,"type":37},"2026-01-30",{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":334,"leadSponsor":335,"locationsCount":45},"100621421","the-analgesic-efficacy-and-safety-of-flurbiprofen-patch-in-patients-with-herpes-zoster-100621421","NCT07370402","The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Topical Patches (Flurbiprofen Patch) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of applying flurbiprofen patch;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the flurbiprofen patch;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding.",{"count":174,"type":22},[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Topical NSAIDs offer a promising alternative by delivering localized analgesia with reduced systemic exposure. Therefore, investigators hypothesize that flurbiprofen patch may effectively reduce the severity of HZ pain without significantly increasing adverse events.",[29,155],{"date":332,"type":37},"2026-01-27",{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":350,"locationsCount":45},"100621420","the-analgesic-efficacy-and-safety-of-tulodesvenlafaxine-in-patients-with-herpes-zoster-100621420","NCT07370389","The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Tulodsesvenlafaxine) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of taking tulodesvenlafaxine;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the tulodesvenlafaxine;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding;\n* 6\\. Suffering from acute or chronic pain disorders other than HZ.",{"count":174,"type":22},[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of antidepressants, which have central antinociceptive property and may offer analgesic benefits by modulating central nervous system pain pathways through increased serotonin and norepinephrine availability. Therefore, investigators hypothesize that tulodesvenlafaxine may effectively reduce the severity of HZ pain without significantly increasing adverse events.",[29,155],{"date":332,"type":37},{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":364,"leadSponsor":365,"locationsCount":45},"100622009","the-analgesic-efficacy-and-safety-of-baclofen-in-patients-with-herpes-zoster-100622009","NCT07378046","The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Baclofen) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of taking baclofen;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the baclofen;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding;\n* 6\\. Suffering from acute or chronic pain disorders other than HZ.",{"count":174,"type":22},[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of muscle relaxant, which can relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. Therefore, investigators hypothesize that baclofen may effectively reduce the severity of HZ pain without significantly increasing adverse events.",[29,155],{"date":316,"type":37},{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":381,"leadSponsor":382,"locationsCount":45},"100620760","the-analgesic-efficacy-and-safety-of-desvenlafaxine-in-patients-with-herpes-zoster-100620760","NCT07361809","The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Desvenlafaxine) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of taking desvenlafaxine;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the desvenlafaxine;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding;\n* 6\\. Suffering from acute or chronic pain disorders other than HZ.",{"count":174,"type":22},[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of antidepressants, which have central antinociceptive property and may offer analgesic benefits by modulating central nervous system pain pathways through increased serotonin and norepinephrine availability. Therefore, investigators hypothesize that desvenlafaxine may effectively reduce the severity of HZ pain without significantly increasing adverse events.",[29,155],"2026-01-21",{"date":379,"type":37},"2026-01-23",{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":399,"locationsCount":45},"100616620","the-analgesic-efficacy-and-safety-of-crisugabalin-in-patients-with-herpes-zoster-100616620","NCT07307976","The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Crisugabalin) in Patients With Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 90 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. History of taking gabapentin or pregabalin;\n* 2\\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;\n* 3\\. History of intolerance or hypersensitivity to any active components or excipient of the crisugabalin;\n* 4\\. History of systemic immune diseases, organ transplantation, or cancers;\n* 5\\. Pregnancy or breastfeeding.",{"count":174,"type":22},[118],"Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Gabapentinoids such as gabapentin and pregabalin are recommended adjuncts, but their efficacy in acute HZ is inconsistent and often accompanied by adverse effects that limit tolerability. Crisugabalin, a newer gabapentinoid approved for peripheral neuropathic pain, has higher affinity and slower dissociation from the α2δ-1 subunit, suggesting stronger analgesia with fewer central side effects. However, its role in managing acute HZ pain remains unknown. We therefore hypothesize that adding crisugabalin to conventional therapy will provide superior pain relief compared with standard treatment alone, and propose a prospective, randomized, controlled, open-label, blinded-endpoint trial to evaluate this.",[29,155],"2026-01-13",{"date":396,"type":37},"2026-01-14",{"date":160,"type":37},{"date":162,"type":22},{"name":164,"class":165},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100620210","phase-2-immunogenicity-and-safety-of-sys6017-in-the-participants-aged-40-years-and-above-100620210","NCT07354659","Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","A Randomized, Blinded, Placebo- and Active-Controlled, Adaptive Phase 2 Study to Evaluate the Immunogenicity and Safety of SYS6017 (a Herpes Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years and Above","Inclusion Criteria:\n\n* 1\\. Individuals aged 40 years or older;\n* 2\\. Able to understand the study procedures, comply with the protocol requirements to attend all the scheduled visits, voluntarily consent to participate in the study, and sign the informed consent form;\n* 3\\. Is physically eligible at the discretion of investigators based on medical history inquiry and physical examination; For participants with chronic underlying diseases (e.g., diabetes mellitus, hypertension, hyperlipidemia and other chronic conditions), they may be enrolled if their conditions have been well controlled within 3 months prior to enrollment in this study (i.e., additional medical interventions or major adjustments to treatments are not required);\n* 4\\. For female participants of childbearing potential: No sexual activity or effective contraceptive methods were used within one menstrual cycle before enrollment; No pregnancy plans and agree to adopt effective contraceptive methods within 8 months after enrollment.\n\nExclusion Criteria:\n\n* 1\\. History of zoster;\n* 2\\. History of vaccination with varicella vaccine or zoster vaccine (including investigational vaccine);\n* 3\\. Axillary temperature ≥ 37.1℃ on the day of enrollment or within 24 h before enrollment;\n* 4\\. History of allergy to any component of the investigational vaccine; or history of severe allergic reactions to vaccines or medications (including but not limited to anaphylaxis, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, or Arthus reaction);\n* 5\\. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that could increases the risk of myocarditis or pericarditis\n* 6\\. History of demyelinating diseases, including but not limited to Guillain-Barré syndrome, multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis, etc.;\n* 7\\. Current epilepsy or convulsion, severe neurological or psychiatric disorders;\n* 8\\. Have contraindications to intramuscular injection, e.g., diagnosed thrombocytopenia, any coagulation disorders, or ongoing treatment with anticoagulants, etc.;\n* 9\\. Active malignant tumor, malignant tumor without adequate treatment, malignant tumor with a potential risk of recurrence during the study;\n* 10\\. Active, unstable, severe or uncontrolled cardiovascular and cerebrovascular diseases, thrombotic diseases, blood and lymphatic system diseases, liver and kidney diseases, respiratory diseases, metabolic diseases, musculoskeletal diseases, autoimmune diseases, etc;\n* 11\\. History of diagnosed immunocompromise or immunosuppression, congenital or functional asplenia, or splenectomy before enrollment;\n* 12\\. Long-term (defined as more than 14 consecutive days) systemic use of immunosuppressants, immunostimulants, or other immunomodulatory drugs (e.g., corticosteroids at a dose of ≥ 20 mg\u002Fday prednisone or equivalent) within 6 months prior to enrollment; however, inhaled and topical corticosteroids are permitted; or planned administration of the aforementioned agents during the study period;\n* 13\\. Administration of whole blood, plasma, serum, immunoglobulin, or monoclonal antibodies within 3 months prior to enrollment, or planned administration of the aforementioned products during the study period;\n* 14\\. Blood donation or blood loss ≥ 450 mL within one month before enrollment, or planning to donate blood during the study;\n* 15\\. Vaccination with any other vaccines within 30 days prior to enrollment, or planned vaccination with any other vaccines within 30 days after the last dose of the study vaccine;\n* 16\\. Current participation in or planned participation in other clinical trials during the study period;\n* 17\\. For female participants of childbearing potential: positive pregnancy test result prior to enrollment, current pregnancy or lactation, or planned pregnancy within 8 months after enrollment;\n* 18\\. Unable to comply with the study procedures and requirements, or presence of other conditions that make the participant inappropriate for this clinical trial, as judged by the investigators.",{"count":408,"type":22},800,[26],"Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled \"A Randomized, Blinded, Placebo- and Active-Controlled, Adaptive Phase 2 Clinical Trial to Evaluate the Immunogenicity and Safety of SYS6017 (a Herpes Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years and Above\".",[29],"2026-01-12",{"date":377,"type":37},{"date":415,"type":22},"2026-01-10",{"date":417,"type":22},"2027-05-31",{"name":419,"class":76},"CSPC Megalith Biopharmaceutical Co.,Ltd.",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":444},"100600566","phase-4-efficacy-and-safety-of-brivudine-in-the-treatment-of-herpes-zoster-100600566","NCT07099157","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Signed Informed Consent Form;\n3. Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:\n\n   * Barrier methods: Condom or barrier cap (diaphragm or cervical cap);\n   * Intrauterine device (IUD) or intrauterine system (IUS);\n   * Surgical sterilization (bilateral oophorectomy with\u002Fwithout hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;\n   * Other investigator-confirmed highly effective physical contraception.\n\nExclusion Criteria:\n\n1. Allergy to brivudine, famciclovir, or penciclovir;\n2. Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);\n3. Cancer patients currently undergoing chemotherapy;\n4. Pregnant or lactating women;\n5. Parkinson's disease;\n6. Any condition deemed inappropriate for study participation by the investigator.",{"count":428,"type":22},140,[57],"This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3\u002FDay 7\u002FDay 14\u002FDay 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.",[29],[29,433,434,435],"Brivudine","pain","treatment","2025-12-28",{"date":438,"type":37},"2026-01-02",{"date":440,"type":37},"2025-08-25",{"date":162,"type":22},{"name":443,"class":165},"Peking University Third Hospital",4,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":17,"sex":18,"minAge":192,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":458,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":479,"locationsCount":4},"100608764","phase-2-a-phase-2-study-to-describe-the-safety-reactogenicity-and-immunogenicity-of-herpes-zoster-in001-mrna-vaccine-in001-in-healthy-participants-100608764","NCT07205796","A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants","A Phase 2, Randomized, Multicenter, Active-controlled, Double-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a 2-dose Regimen of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 79 Years Old","Key Inclusion Criteria:\n\n1. Male or female adults, of any race or ethnicity, between 50 and 79 years of age, inclusive, at Screening.\n2. Male and female participants must have a body mass index between 18.5 and 34.9 kg\u002Fm\\^2, inclusive, at Screening, and body weight ≥ 50 kg for males and ≥ 45 kg for females.\n3. Participants must be able to freely provide documented informed consent prior to study procedures being performed.\n4. Participants must be in good general health as determined by comprehensive evaluation by Investigators at the time of enrollment.\n5. Participants with asymptomatic medical conditions that are not associated with end-organ damage may be include provided that they are being appropriately treated as per standard of care, are clinically stable, and are not receiving treatments what would be exclusionary in the opinion of the Investigator.\n6. Participants must be able and agree to comply with all study visits and procedures (including blood tests, diary completion, receipt of telephone calls from the site, willingness to be available for unscheduled clinic visits).\n7. Females of reproductive age will not be pregnant or lactating.\n8. Females of childbearing potential, who are sexually active and at risk for pregnancy with their partner(s), must have used appropriate method of contraception at least 30 days prior to enrollment and agree to use a highly effective method of contraception consistently and correctly from enrollment to Study Day 236 (6 months after second vaccination). The Investigator or designee, in consultation with the participant, will confirm that the participant has selected an appropriate method of contraception for the individual participant and his or her partner from the list of appropriate contraception methods and will confirm that the participant has been instructed in its consistent and correct use.\n9. Participants must be willing to refrain from blood donation throughout study participation.\n\nKey Exclusion Criteria:\n\n1. Participants with a known history of HZ.\n2. Participants with a known history of GBS, encephalomyelitis, or transverse myelitis.\n3. Participants with a known history of severe heart disease (i.e., heart failure, recent coronary artery disease, myocarditis, pericarditis, or cardiomyopathy).\n4. Participants with acute medical illness or febrile illness, including oral temperature ≥ 38.0°C (≥ 100.4°F) within 1 day prior to Screening. These individuals may be offered the opportunity to enter the study after the fever and\u002For acute illness has been resolved.\n5. Participants with any medical, neurological, or psychiatric condition that, in the opinion of the Investigator, could place the participant at an unacceptable risk of injury or render the participant unable to comply with all study procedures and achieve successful completion of the trial.\n6. Participants with a known history of hypersensitivity reactions including anaphylaxis and urticaria, or other significant adverse reactions to IN001 or its excipients; or participants with a known history of severe allergic reaction (e.g., anaphylaxis) to any mRNA vaccine (e.g., COVID-19 mRNA vaccine, RSV mRNA vaccine), any component of SHINGRIX\\^TM, or after a previous dose of SHINGRIX\\^TM.\n7. Participants who have a positive pregnancy test at the screening visit or who intend to become pregnant during or breastfeed through Study Day 236 (6 months after second vaccination).\n8. Participants with uncontrolled hypertension (supine systolic blood pressure \\[BP\\] \\> 140 mmHg or supine average diastolic BP \\> 90 mmHg at Screening). Eligibility may be reassessed with a single repeat measurement at the Investigator's discretion, and the repeat value will be used for determination.\n9. Participants with a history of significant hematologic abnormalities or history of thrombosis with thrombocytopenia syndrome.\n10. Participants with hematology and\u002For clinical chemistry laboratory result(s) that meet the definition of a Grade ≥ 2 abnormality as delineated in the FDA guidance. However, if the institutional normal reference ranges differ from those defined by the region or site, exceptions may be considered on a case-by-case basis with the agreement of the Investigator and the Sponsor.\n11. Participants with a history of congenital or acquired immunodeficiency.\n12. Participants with an immunosuppressive or immunodeficient state, asplenia, or recurrent severe infections.\n13. Participants with a known history of chronic infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis.\n14. Positive HBV and HCV panel and\u002For positive HIV test. Participants whose results are compatible with prior immunization (indicating evidence of protection) may be included at the discretion of the Investigator that take into account factors such as the timing and effectiveness of the previous immunization.\n15. Participants with positive syphilis test.\n16. Participants with chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial participation or interpretation of study results.\n17. Participants with a known history of vaccination against varicella or HZ.\n18. Participants who have received immunoglobulins and\u002For any blood or blood products within 4 months before the first study vaccination or who plan to receive such products at any time during the study.\n19. Participants who have received immunomodulatory, immunostimulatory, or immunosuppressant drugs including interferon and cytotoxic drugs within 3 months of Screening (or 5 half-lives, whichever is longer) or who plan to receive them across the duration of the study.\n20. Participants requiring systemic corticosteroids exceeding 10 mg\u002Fday of prednisone equivalent for ≥ 10 days within 30 days of Screening. The use of topical, ophthalmic, inhaled, and intranasal steroid preparations will be permitted.\n21. Participants who have received or plan to receive any licensed vaccine ≤ 28 days prior to the first vaccination (Day 0) or who plan to receive a licensed vaccine ≤ 28 days after the first study vaccination or ≤ 28 days before or after the second study vaccination. The only exception is licensed inactivated influenza vaccine or non-replicating influenza vaccine, which may be given ≥ 14 days before or ≥ 28 days after receipt the first or second study vaccination.\n22. Participants receiving treatment with another investigational drug, biological agent, or device ≤ 28 days of Screening, or 5 half-lives of the investigational drug, whichever is longer; or currently enrolled in or plans to participate in another clinical trial with an investigational agent during the study period (including the follow-up period of the study).\n23. Participants with history of drug abuse within 1 year prior to Screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to Screening.\n24. History of alcohol abuse within 1 year prior to Screening or regular use of alcohol within 6 months prior to Screening that exceeds 10 units for women or 15 units for men of alcohol per week.\n25. Positive alcohol breath test result or positive urine drug screen (UDS) caused by misuse of soft drugs, hard drugs or abuse of any other concomitant medications at Screening and\u002For on Study Day 0.\n26. Participants who are Investigator site staff members, employees of the Sponsor or the clinical research organization directly involved in the conduct of the study, or site staff members otherwise supervised by the Investigator or immediate family members of any of the previously mentioned individuals.\n27. Participants with a demonstrated inability to comply with the study procedures.\n28. Anything that the Investigator considers would jeopardize the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.","79 Years",{"count":454,"type":22},480,[26],"The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 79 years of age.",[29],[459,270,460,461,462,463,200,464,465,466,467,468,202,469,470,95,94,93,96,471,472],"IN001","Vaccine","Varicella-zoster Virus","VZV","Viral Diseases","Messenger RNA","Herpes Zoster (HZ)","Skin Diseases, Infectious","Safety","Reactogenicity","Innorna","Shenxin","Skin Diseases, Viral","Skin Diseases","2025-10-04",{"date":475,"type":37},"2025-10-07",{"date":138,"type":22},{"date":478,"type":22},"2027-12-30",{"name":480,"class":76},"Shenzhen Shenxin Biotechnology Co., Ltd",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":4},"100589469","phase-1-safety-and-immunogenicity-of-sys6017-in-healthy-participants-aged-40-years-or-more-100589469","NCT06954818","Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More","A Randomized, Observer-blind, Placebo-controlled, Adaptive Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6017(a Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years or More","Inclusion Criteria:\n\n* 1\\. Healthy participants aged 40 years or more;\n* 2\\. Be able to understand the study procedures and comply with the requirements of the protocol for the scheduled visits, voluntarily consent to participate in the study and sign the informed consent form (ICF);\n* 3\\. Being in good health at the discretion of investigators based on medical history inquiry, physical examination, laboratory test and electrocardiograph examination;\n* 4\\. For female participants of childbearing potential: no sexual activity or used effective contraceptive methods within one menstrual cycle before enrollment; no pregnancy plans and agree to used effective contraceptive methods with 8 months after enrollment.\n\nExclusion Criteria:\n\n* 1\\. History of zoster;\n* 2\\. History of vaccination with varicella vaccine or zoster vaccine (including investigational vaccine);\n* 3\\. Axillary temperature ≥ 37.1℃ on the day of enrollment or within 24 h before enrollment;\n* 4\\. Have abnormal test or examination result that is of Grade 1 (inclusive) or more in accordance with the Guidelines for Adverse Event Grading Standards for Clinical Trials of Preventive Vaccines (2019) issued by China National Medical Products Administration or other applicable adverse event grading standards referred in the protocol;\n* 5\\. History of allergy to any component of the investigational vaccine, or history of severe allergic reaction (including but not limited to anaphylaxis, allergic laryngeal edema, Henoch-Schonlein purpura, thrombocytopenia purpura or Arthus reaction) to vaccines or medicines;\n* 6\\. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that would increase the risk of myocarditis or pericarditis;\n* 7\\. History of demyelinating diseases, including but not limited to Guillain-Barré syndrome, multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis, etc.\n* 8\\. Current epilepsy or convulsion, severe neurological or psychiatric disorders;\n* 9\\. Have contraindications to intramuscular injection, e.g., diagnosed thrombocytopenia, any coagulation disorders, or current treatment with anticoagulants, etc;\n* 10\\. Active malignant tumor, malignant tumor without adequate treatment, malignant tumor with a potential risk of recurrence during the study;\n* 11\\. Active, unstable, severe or uncontrolled cardiovascular and cerebrovascular diseases, thrombotic diseases, blood and lymphatic system diseases, liver and kidney diseases, respiratory diseases, metabolic diseases, musculoskeletal diseases, autoimmune diseases, etc;\n* 12\\. Have diagnosed immunocompromise or immunosuppression, congenital or functional asplenia, or splenectomy;\n* 13\\. Have received immunosuppressants, immunostimulants, or other immunomodulatory medicines (e.g., corticosteroids, ≥ 20 mg\u002Fd prednisone or equivalent) for a long time (defined as 14 days or more), within 6 months before enrollment, or planning to receive the aforementioned medicines during the study; inhaled and topical steroids are allowed;\n* 14\\. Have received whole blood, plasma, serum, immunoglobulins, or monoclonal antibodies within 3 months before enrollment, or planning to receive these products during the study;\n* 15\\. Blood donation or blood loss ≥ 450 mL within 1 month before enrollment, or planning to donate blood during the study;\n* 16\\. Have received any other vaccine within 30 days before enrollment, or planning to receive any other vaccine within 30 days after the last dose;\n* 17\\. Currently participating in or planning to participate in other clinical trials during the study;\n* 18\\. For female participant of childbearing potential: having positive urine pregnancy test, being in pregnancy or lactation before enrollment;\n* 19\\. Unable to comply with the study procedures or adhere to the study requirements, or there are other conditions that make the participation in this study inappropriate, as determined by the investigators.",{"count":489,"type":22},200,[25],"Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. This randomized, observer-blind, placebo-controlled, adaptive phase 1 trial aims to evaluate the safety and immunogenicity of an investigational zoster mRNA vaccine in healthy participants aged 40 years or more.",[29],"2025-05-05",{"date":495,"type":37},"2025-05-08",{"date":497,"type":22},"2025-05-10",{"date":499,"type":22},"2026-11-10",{"name":419,"class":76},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":45},"100586348","esketamine-combined-with-prf-of-drg-for-acutesubacute-zoster-associated-pain-100586348","NCT06914206","Esketamine Combined With PRF of DRG for Acute\u002FSubacute Zoster-associated Pain","Esketamine Intravenous Infusion Combined With Pulsed Radiofrequency of Dorsal Root Ganglion for Acute and Subacute Herpes Zoster Neuralgia: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Ages more than 18 years;\n2. Patients with onset of herpes zoster (HZ) rash less than 90 days;\n3. HZ affected the spinal nerves (cervical\u002Fthoracic\u002Flumbar nerve);\n4. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)；\n5. Planned to perform CT-guided PRF treatment of the dorsal root ganglion(DRG).\n\nExclusion Criteria:\n\n1. Obstructive sleep apnoea syndrome;\n2. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.\n3. A history of systemic immune diseases, organ transplantation, or cancers;\n4. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;\n5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;\n6. Comorbid hyperthyroidism or phaeochromocytoma;\n7. Recent history of drug abuse;\n8. Having contraindications to esketamine;\n9. Communication difficulties.\n10. Women who are preparing for pregnancy, in the pregnancy or lactation period.",{"count":222,"type":22},[118],"To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute\u002Fsubacute zoster-associated pain (ZAP) patients.",[29],[513,514],"Herpes Zoster Neuralgia","Esketamine","2025-04-05",{"date":517,"type":37},"2025-04-09",{"date":519,"type":22},"2025-04-01",{"date":521,"type":22},"2026-07-01",{"name":164,"class":165},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":45},"100583914","subcutaneous-lidocaine-injection-in-acute-herpes-zoster-neuralgia-and-post-herpetic-neuralgia-100583914","NCT06882525","Subcutaneous Lidocaine Injection in Acute Herpes Zoster Neuralgia and Post-herpetic Neuralgia","The Evaluation of the Effectiveness of Subcutaneous Lidocaine Injection in Acute Herpes Zoster Neuralgia and Post-herpetic Neuralgia","SCL-HZ\u002FPHN","Inclusion Criteria:\n\n* patients over the age of 18\n* with acute HZ pain (rash duration \\\u003C 30 days\n* pain due to PHN (rash duration \\> 3 months),\n\nExclusion Criteria:\n\npatients on anticoagulants or have coagulation disorders, patients with psychomotor disorders patients with uncontrolled diabetes patients with bacterial infection or infectious discharge in the affected dermatomal region patients allergic to lidocaine patients with lesions in the facial or genital regions pregnant or breastfeeding patients",{"count":532,"type":22},76,[118],"In this study, it was aimed to compare the effect of subcutaneous lidocaine injection, which is routinely applied in pain clinic,in patients who present with pain complaints due to acute herpes zoster and post-herpetic neuralgia, and investigate its contribution to preventing the development of post-herpetic neuralgia",[29,536],"Neuralgia, Postherpetic",[536,31,538],"Lidocaine","2025-03-17",{"date":541,"type":37},"2025-03-18",{"date":543,"type":22},"2025-03-07",{"date":545,"type":22},"2025-12-06",{"name":547,"class":165},"Ankara City Hospital Bilkent",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":45},"100577685","phase-1-a-study-to-evaluate-the-safety-tolerability-and-immunogenicity-of-a-recombinant-herpes-zoster-vaccine-100577685","NCT06801509","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","A Randomized, Double-blind, Controlled Phase I\u002FII Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Recombinant Herpes Zoster Vaccine in Healthy Adults","Inclusion Criteria:\n\n1. Male or female subjects ≥ 40 years of age;\n2. The subject can and fully understand the trial procedures and voluntarily sign the ICF;\n3. The subject is in a healthy state or has stable underlying diseases according to investigator's assessment based on medical history and related physical examination results;\n4. The subject can comply with the requirements of the protocol;\n5. The axillary temperature of the subject is \\\u003C 37.0℃ on the day of enrollment;\n6. Fertile men and women with childbearing potential voluntarily agree to take effective contraceptive measures from the first vaccination to at least 90 days after the last dose of study vaccines.\n\nExclusion Criteria:\n\n1. History of herpes zoster before enrollment, or close contact with a varicella\u002Fherpes zoster patient within 30 days prior to enrollment;\n2. Previous vaccination against herpes zoster and varicella (including vaccines that have been registered or under clinical research);\n3. Allergic to any component of the study vaccine, or history of severe allergy to any vaccination, such as anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis reaction, angioneurotic edema, etc.\n4. History or family history of convulsions, epilepsy, and psychiatric disorders;\n5. Suffering from serious chronic diseases or in the active stage of chronic diseases, which are evaluated by the investigator to affect the trial observation, including but not limited to myocardial infarction, severe arrhythmia, unstable angina, hypertension that cannot be controlled after drug treatment (subjects 40-59 years of age have systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg, and subjects ≥60 years of age have systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg), diabetes with severe complications, cancer or precancerous lesions, and other serious cerebrovascular diseases, heart disease, respiratory diseases, liver and kidney diseases, and thyroid diseases;\n6. Primary or secondary immunosuppressive condition, or diagnosed with primary or acquired immunodeficiency disease, human immunodeficiency virus (HIV) infection, etc.\n7. History of thrombocytopenia or other coagulation disorders, which may cause contraindications for intramuscular injection and venous blood collection;\n8. Fever (axillary temperature ≥37.3℃) within 3 days before enrollment or systemic antibiotic or antiviral treatment within 7 days;\n9. Use of antipyretic analgesics or other drugs with antipyretic and analgesic effects, such as acetaminophen and ibuprofen, within 72 h before vaccination.\n10. Abnormal laboratory test (blood routine, blood biochemistry, urine routine) results that are outside the reference range and clinically significant (only apply to Phase I);\n11. Those who are pregnant (positive urine pregnancy test) or breast-feeding, or those who plan to become pregnant during the study period;\n12. Long-term or high-dose corticosteroid therapy (duration ≥15 days, or dose ≥1 mg\u002Fkg\u002F day of prednisone or equivalent doses of other corticosteroids), or other immunosuppressive and cytotoxic therapy within 90 days prior to vaccination. Short-term or topical use (such as ointments, eye drops, inhalants, intra-articular medications or nasal sprays) of glucocorticoids is permitted;\n13. Vaccination with non-attenuated vaccines within 14 days before the first dose of study vaccines, or with live-attenuated vaccines within 28 days before the first dose of study vaccines;\n14. Participation in other clinical trials (drug or vaccine) within 30 days preceding the first dose of study vaccines or planning to participate in other clinical trials before this clinical study is completed;\n15. Asplenia or functional asplenia;\n16. Those who are known to have been diagnosed or currently have an infectious disease, including hepatitis B, hepatitis C, syphilis or AIDS;\n17. Those who have any acute illness or acute onset of chronic illness within 72 hours before the first dose of vaccination;\n18. Those who have received blood or blood-related products, including immunoglobulins, within 3 months before the first dose of vaccination, or have planned to use them during the study period;\n19. Subjects deemed by the investigator to have other conditions that render them ineligible to participate in this study, which include but are not limited to those who are incapable of participating in follow-up visits based on the protocol.",{"count":556,"type":22},540,[25,26],"The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.",[29],"2025-01-24",{"date":562,"type":37},"2025-01-30",{"date":564,"type":22},"2025-02-15",{"date":566,"type":22},"2027-10-10",{"name":568,"class":76},"Sinocelltech Ltd.",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":45},"100566401","phase-3-phase-iii-clinical-trial-of-lot-to-lot-consistency-of-recombinant-herpes-zoster-vaccine-cho-cell-100566401","NCT06654700","Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced At a Commercial Scale in Subjects Aged 40 Years and Older.","Inclusion Criteria:\n\n1. A male or female permanent resident aged 40 years and older at enrollment, with valid identity;\n2. Subjects voluntarily agree to participate in the study and signed an informed consent;\n3. Be able to understand clinical trials, participate in all scheduled visits and comply with the protocol requirements(e.g. completion of the diary cards\u002Fquestionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);\n4. Women of childbearing potential plan to avoid pregnancy and are willing to use effective contraception(e.g. oral contraceptive pills, injectable progestogen, percutaneous contraceptive patches, implants of levonorgestrel, intrauterine device, female and male sterilization or abstinence) within 12 months after the last vaccination, and the uses of the rhythm method alone, withdrawal alone, and emergency contraception, are not acceptable.\n\nExclusion Criteria:\n\n1. Axillary temperature \\> 37.0°C on the day of vaccination or acute illness;\n2. Current or history of herpes zoster;\n3. Previous vaccination against varicella or herpes zoster (either registered product or participation in a previous vaccine study);\n4. Pregnant (urine pregnancy test was positive) or lactating female;\n5. Receipt of live vaccine within 28 days, or any other vaccine within 14 days prior to vaccination;\n6. Receipt of immunoglobulin or intravenous immunoglobulin during 3 months before vaccination, or planned receipt 1 month post the last vaccination;\n7. Acute diseases(such as acute upper respiratory tract infection with fever, cough, sore throat) or acute exacerbation of chronic disease within 3 days before vaccination;\n8. Receipt of antipyretic, analgesic and allergy drugs within 3 days before vaccination, except enteric-coated aspirin for cardiovascular diseases prevention;\n9. A known allergy to any components of the study vaccine, or history of severe allergy (e.g. Anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, Arthus reaction, severe urticaria) to any previous vaccination;\n10. Allergy to aminoglycoside antibiotics;\n11. History of convulsions, epilepsy, congenital brain dysplasia, mental illness or family history, or history of brain nerve tissue damage due to other severe neurological disorders(e.g. brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, chemical drug poisoning);\n12. Asplenia or functional asplenia, or splenectomy caused by any condition;\n13. Primary or secondary impairment of immune function, diagnosed congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease or other autoimmune diseases;\n14. Receipt of Immunosuppressive therapy(such as long-term use of systemic glucocorticoid ≥14 days, ≥20mg\u002Fday prednisone or equivalent dose) or long-acting immune-modifying drugs(e.g. Infliximab) during the period starting 6 months before vaccination or planned administration 1 month after the last vaccination, but topical steroids(e.g. ointment, eye drops, inhalants, nasal sprays) that do not exceed the dosage recommended in the instructions or have any systemic signs are acceptable;\n15. Patients with severe chronic diseases, including but not limited to severe cardiovascular diseases (pulmonary heart disease, pulmonary edema), severe liver and kidney diseases, and diabetes mellitus with complications;\n16. History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection contraindications;\n17. Abnormal and uncontrolled blood pressure during physical examination before vaccination (for subjects aged 40-59: systolic pressure ≥ 140 mmHg and\u002For diastolic pressure ≥ 90 mmHg; for subjects aged ≥60, systolic pressure ≥ 150 mmHg and\u002For diastolic pressure ≥ 100 mmHg);\n18. History of drug abuse (narcotic drugs, psychotropic drugs);\n19. Patients with previous or current malignant tumors (except papillary thyroid cancer);\n20. Receipt of investigational or unapproved products (drugs or vaccines) within 6 months before vaccination; or planned participation in another clinical study during the study period;\n21. Any condition that, in the opinion the investigator, makes subjects ineligible for the study.",{"count":577,"type":22},1200,[579],"PHASE3","To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.",[29],"2024-11-18",{"date":584,"type":37},"2024-11-20",{"date":586,"type":22},"2024-12-09",{"date":588,"type":22},"2025-05-01",{"name":590,"class":76},"MAXVAX Biotechnology Limited Liability Company"]